Basking is developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS). The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases conducted by company founders Bruce Sullenger and Dr. Shahid Nimjee at Duke University and The Ohio State University Wexner Medical Center.
The Company’s candidate drug, BB-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF). Basking is co-developing a matched oligonucleotide reversal agent, BB-025, for as-needed, rapid reversal of BB-031. Basking’s paired therapy has the potential to extend the treatment window, significantly expand the population of patients that receive acute thrombolytic therapy and aligns perfectly with the urgent need in medicine for precision-based therapeutics in cardiovascular disease.
BB-031, originally named DTRI-031, is an RNA aptamer that potently and rapidly inhibits the A1 domain of von Willebrand Factor (vWF). Targeting vWF, a key mediator of platelet rich clot formation and stability, represents a novel approach to improve the overall efficacy of pharmacological revascularization. BB-031 has demonstrated successful recanalization of occluded arteries in multiple animal models including a canine model of cerebrovascular stroke.
67% reduction in stroke volume by MRI
BB-025 is a rationally designed reversal agent that neutralizes BB-031 activity and normalizes hemostasis within minutes of administration in the event of bleeding. Immediate restoration of normal hemostasis will enable surgeons to intervene and address the bleed, thereby limiting associated downstream morbidity and mortality.
BB-031, previously known as DTRI-031, entered clinical development in Q3 2021, and the phase 1 clinical study will be completed by Q2 2022. A Phase 2 program will be initiated in late 2022. BB-025, previously DTRI-025, is continuing IND-enabling development.